Comparative Pharmacology
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus PITRESSIN TANNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus PITRESSIN TANNATE.
DDAVP (NEEDS NO REFRIGERATION) vs PITRESSIN TANNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
0.5-1 mL (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog